Adoption of direct-acting antiviral medications for hepatitis C: a retrospective observational study
Abstract Background Approximately 3.5 million Americans are infected with the hepatitis C virus (HCV). Although many patients with HCV are asymptomatic, HCV is the leading cause of infection-related death in the U.S. With advances in curative medication therapy for HCV, many of these deaths are prev...
Main Authors: | Leah L. Zullig, Haresh L. Bhatia, Ziad F. Gellad, Mark Eatherly, Rochelle Henderson, Hayden B. Bosworth |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-07-01
|
Series: | BMC Health Services Research |
Online Access: | http://link.springer.com/article/10.1186/s12913-019-4349-x |
Similar Items
-
Lessons learned from two randomized controlled trials: CITIES and STOP-DKD
by: Leah L. Zullig, et al.
Published: (2020-09-01) -
Retrospective Evaluation on Patient Screening and Counseling Service on Direct-acting Antivirals Against Hepatitis C
by: Bob Ka Him Wong, et al.
Published: (2020-05-01) -
Mexican experience with direct-acting antivirals in the treatment of hepatitis C
by: J.L. Pérez Hernández, et al.
Published: (2020-09-01) -
Characterisation of Hepatitis C Virus antiviral resistance in the era of direct acting antivirals
by: Smith, D
Published: (2019) -
Direct-acting antivirals for chronic Hepatitis C are effective and safe: an observational study in Londrina/PR
by: Hodnei Takashi Machado, et al.
Published: (2022-08-01)